wintop healthcare fund
TRANSCRIPT
-
WINTOP HEALTHCARE FUND
-
DISCLAIMER
Anyinforma+oncontainedwithinthispresenta+onshouldnotbedeemedtocons+tuteinvestmentadviceandshouldnotberelieduponasthebasisforadecisiontoenterintoatransac+on,orasthebasisforanyfinancialorinvestmentdecision.Investorsshouldalwaysseekprofessionaladviceinregardtothesuitabilityofanyinvestment.WintopCapitalPte.Ltd.acceptsnoliabilityforanylossesorconsequen+allossincurredbyinvestorsac+nguponanyinforma+oncontainedwithinthispresenta+on.Thevalueofinvestmentsandtheincomearisingfromthem,candecreaseaswellasincrease,andarenotguaranteed,whichmeansthataninvestormaynotgetbackwhattheyinvested.Changesinexchangeratesmayalsocausean investmenttofluctuate invalue.Levelsof taxa+onsdependonan investor's individualcircumstancesandthevalueofanyapplicabletaxreliefs.
-
WINTOP CAPITAL: A MAS-REGISTERED FUND MANAGER
WINTOPHEALTHCARE
FUND
(PrivateLimitedCompany)
WINTOPCAPITALPTE.LTD.
(RegisteredFundManager)
FOUNDERSHeLiMin
LeongMunWai
-
EXECUTIVE SUMMARY
Insa6ableDemand BalancedStrategy SuperiorReturn
HighMission CoreCompetencies
Insa+abledemandformoreandbeMerhealthcareproductsandservicesinAsiawhosepopula+onisincreasinglyaffluentandrapidlyageingatthesame+me.Thereisalsoapoli+calandsocialurgencyinmostAsiancountriestoprovideatleastaminimumlevelofhealthcarecoveragetotheirci+zens.
WintopHealthcareFund(WHF)seektoinvestininvesteeswhocontributetothecrea+onofamoreefficientandeffec+vehealthcaresystemwithagreateremphasisonpreven+onandwell-beingtoimprovegeneralhealthandqualityoflife.
WHFsinvestmentstrategyistohaveabalancedporTolioofinvestments40%intechnologyandR&Ddrivencompaniesand60%inopera+nghealthcareen++esthatarealreadygenera+ngacashflow.
Wintopsinvestmentteampossessesthreecorecompetenciesdomainknowledge,China/Japanconnec+onandcapitalmarketexperiencewhichenablesittofindthoseinvesteesandgrowthemtosuccess.
WHFiswell-posi+onedtodeliverasuperiorannualreturnof20%p.a.
1 2 3 4 5
-
HEALTHCARE: A DYNAMIC SECTOR WITH ATTRACTIVE GROWTH OPPORTUNITIES
Globalhealthcarespending$9.3trillion
(projected2018)
$2.2trillionInASIA
RiseofAsia
Asiaisnowthemostexci+ngpartoftheworldforhealthcarebusinesseswithageingdemographicsandrapidlyrisingincomesacrosstheregion.
AffluentLifestyle
AffluenceinAsiahasledtosurgeinchronicailmentslikediabetesandcoronarydiseasesandgrowingdemandforhealthcare,includingpreven+veandwell-beinghealthcare.
HealthcareReform
DrivenneedtocontrolhealthcarecostandtoprovidebeMercoverage,thehealthcaresystemisalsoundergoingradicalreformswhichprovideabundantopportuni+esforinnova+vefirms.
WideSpectrum
Healthcareoffersrangeofinvestmentsfromdefensivematurecashgenera+ngassets(clinicchains&establishedpharmacies)toaggressivetargetssuchassmallcapbiotechordrugdiscoverycompaniesthatpoten+allyoffermul+plierreturns.
Cross-BorderInterest
Asianhealthcarecompaniesaregainingconfidenceandhaveincreasinglyseektoexpandacrosstheregiontobuildscaleandwidenscopeofopera+ons.
Globalhealthcarespendingexpectedtoaccelerateataveragerateof5%growthp.ato$9.3trillion*in2018,approx24%($2.2trillion)fromAsia*Worldindustryoutlook:Healthcareandpharmaceu+cals,TheEconomistIntelligenceUnit,May2014
-
INVESTMENT STRATEGY A BALANCED PORTFOLIO
R&D Sector,
[VALUE] Medical Services Sector,
[VALUE]
Approximately 40% of capital to be deployed inmedical technologies, bioscience and research anddevelopment intensive companies (R&D Sector)includingthefollowingsub-sectors: Drugdevelopment Innova+vemedicaldevicesandequipment HealthcaresupplementsandnaturalremediesApproximately 60% of capital to be deployed inconsumer-centricmedical services sectors (MedicalServicesSector)includingthefollowingsub-sectors: Pharmaceu+calproduc+onanddistribu+on Hospital&clinicsandpharmacychains Healthcare services that support the healthcaresystem
-
INVESTMENT PROCESS
RiskFocus
Superiorrisk-adjustedconsistentreturnsof20%p.a.withstrongemphasisonriskratherthansimplycap+vatedbyhugepoten+alreturns.
ValueInves6ng
WHFfocusesoncompaniesthatpossessstrongmanagementandsoundbusinessmodelandseekstoaddvaluethroughfinancialdiscipline,opera+onalandstrategicguidance.
Co-investment
Co-optcredibleco-investorsforvalida+on,riskmi+ga+on&accesstoalargerresourcebasetosupportthegrowthofinvesteecompanies.
Diversifica6on
Diversifica+onofriskbynotinves+ngofmorethan15%oftotalfundinanyproject.
Cross-BorderArbitrage
Undertakecrossborderinvestmentstotakeadvantageofvalua+onarbitrageandtoencourageinvesteecompaniestocapturescaleandscopeeconomiesandbestprac+cesknow-how.
PorTolioSynergy
PorTolioobjec+veistobuildaporTolioofcompaniesthathavesynergyamongthemselvesandcontributetothesuccessofthewhole.
-
CORE COMPETENCIES
CapitalMarket
Experience
ChinaConnec6on
DomainKnowledge
LeongMunWaiOver30yearsofinvestmentbankingexperience: Instrumentalinthesuccessfulini6alpublicofferings(IPOs)ofover100companiesinSGX,HKSEandotherAsianbourses.
ManagingDirectorofaleadingSingaporestockbrokingcompany.
Fundmanagementexperiencewithasovereignwealthfund.
Ma6ldaTanOver30yearsofinvestmentbankingexperience Heldseniorbankingposi6onwithNMRothschild&Sons(Spore&Jakarta).
BoardandInvestmentcommibeememberofAventures1Fundfocusingprimarilyonhealthcareindustry.
HeLiMinPresidentofZhejiangZonebannerJiuzhouGroup,aconglomerateinChinawithbusinessesinpharmaceu6cals,tradi6onalChinesemedicines,chemicals,logis6csandproperty.ZonebanneriscontrollingshareholderofaShanghai-listedpharmaceu6calcompany.HeisinstrumentalinpullinginapanelofmedicalexpertstoprovidespecialistadvicetotheFund.
SimonSunOver40yearsofexperienceinthepetrochemical,chemicalandpharmaceu6calindustry.Heldseniorexecu6veposi6onsinglobalchemicalcompaniesintheUS,EuropeandJapan.
DrHwangChiLooiOver40yearsofR&D,managementandconsul6ngexperienceinglobalpharmaceu6calcompaniesandtheirChinesejointventures.SeniorRegulatoryScien6stoftheSingaporesHealthScienceAuthority.
DrGuZiQiangOver25yearsworkingexperiencesinpharmaceu6calindustry,including15yearswithUSFDAregula6ons,guidance,proceduresintheareaofChemistry,ManufacturingandControls(CMC)andCurrentGoodManufacturingPrac6ce(CGMP).
-
INVESTMENT STRATEGY + CORE COMPETENCIES SUPERIOR RETURNS
BeberInvesteeQuality
StrongerBargainingPower
CapitalMarketsExperience
DomainKnowledge
ChinaConnec6on
BiggerExpertNetwork
SUPERIORRETURNS
-
CONFIRMED DEAL PIPELINE
DrugforPeriodon66s
TheinvesteeisaUKbasedandthemanagementteam comprised of ex-senior execu+ves fromNovar+sPharmaceu+cals.
Reposi+oningofanexis+ngdrugcompoundfortreatment of a prevalent dental disease andpreventtoothloss.
Es+mated market size to be about USD2bncurrently but growing because of ageingpopula+on and greater awareness of gooddentalhealth.
Exit through sale to large pharma alercomple+onofphase2trialsintwoyears.
Expectedannualreturnisover30%p.a.
-
CONFIRMED DEAL PIPELINE
ClinicChain Opera+ngaSingaporebasedclinicchain in
medi-aesthe+cs, dental, ophthalmology,wellnessandspecialistclinics.
Group is currently profitable with posi+vecashflowofSGD6million.
Strategyistoforbrandbuildingandgrowththrough regional expansion and Chinapartnerships
PlantoRTOintoaSGXlistedcointhenext12-24months to poten+ally yield50%+returnp.a. thusproviding liquidityandexitpossibili+es.
-
FUND TERMSHEET
Type Pan-AsiaPharmaceu6cal&HealthcareFundTargetReturn Morethan20%p.aLaunchDate 30June2016Denomina+on UnitedStatesDollar(USD)Domicile SingaporeTargetFundSize USD100millionPre-ClosingDate 30June2016FirstClosingDate 29September2016FinalClosingDate 29June2017MinimumInvestment USD500,000(USDollarFiveHundredThousand)ManagementFee 2%p.a.oncommiMedcapitalPerformanceFee 20%carriedinterestIni+alDrawdown 40%ofcommiMedcapitalInterest 8%p.aoncommiMedcapitalalerfirstclosingdateFundLife 5yrs+2yrsfromfirstclosingdate
-
Thank You!